The Product's primary investment objective is to be exposed to global equities, by systematically applying the investment process developed by the Management Company to outperform the reference index by minimizing risk factor concentration via a maximally diversified portfolio. Equity selection is based on the quantitative and systematic models, which aim to optimize the level of diversification achieved relative to the benchmark indicator. These models determine the optimal model portfolio, including both the list of eligible stocks and their portfolio weightings. The resulting Product, combined with other "long-only" investments, is expected to improve the results of asset allocation by, among other things, improve the Sharpe ratio and reducing volatility. The Product is managed in reference to the Bloomberg Developed Markets Large & Mid Cap Net Return Index. The Product does not use an index-based management strategy, it is actively managed. As a consequence, its performance may differ substantially from the benchmark, which is used to define the investment universe and determine the global risk profile of the Product. A majority of the benchmark"s equity securities will be components of the Product. The weightings of the Product"s portfolio holdings may diverge significantly from their equivalent weighting in the index. Net asset appreciations may be compared to the Bloomberg Developed Markets Large & Mid Cap Net Return Index. Under normal market conditions, at least 90% of the Product's assets are exposed to global equity markets, including the small, mid and large-cap markets. The Product reserves the option to invest up to 100% of its assets in mono-underlying Contracts for Differences (CFDs), if justified by market conditions. CFDs are futures contracts entered into with a counterparty and settled through cash payments rather than through physical delivery of financial instruments. For the purpose of diversification, the Product may invest up to 20% of its assets in Real Estate Investment Trusts (REIT). In order to be continually exposed as closely as possible to the result of the model, the Product may build or add to its exposure through American Depository Receipts (ADRs) and Global Depository Receipts (GDRs), for up to 100% of its net assets, and/or through other OTC contracts in order to enhance risk control and minimize transaction costs. The Product may also use different markets or assets, including derivative instruments to hedge and/or expose the portfolio to equity risk and/or hedge currency risk. The Product's leveraged exposure may not exceed 110%.